Company Analysis
Sign in

Agenus Inc. (AGEN)

Nasdaq: AGEN · Biological Products, (No Diagnostic Substances) · Lexington, MA · filing with the SEC since 1999
Full chart Alerts Compare
Grade4.5
◀ Past 3.5● Present 5.2▶ Future 4.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

66 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Agenus Inc.’s names, not what it holds today.

Patents granted
66
66 utility, 1976 to Dec 31, 2025
Granted in 2025
6
Against 6 in 2024 and 5 in 2023
Applications published
104
4 of them in 2025
Names they are printed under
3
its own name, a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals25
Biotechnology10
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Agenus Inc. its own name
named as the applicant on its applications, in US
0 granted
84 published
AGENUS INC. its own name
US, as the owner printed on each patent
55 granted
12 published
Antigenics, Inc. a former name
US, as the owner printed on each patent
11 granted
8 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 9, 202512,492,393Anti-CD137 antibodies and methods of use thereofBiotechnologyAGENUS INC.
Dec 9, 202512,492,257Anti-CTLA-4 antibodies and methods of use thereofPharmaceuticalsAGENUS INC.
Nov 25, 202512,479,913Polynucleotide encoding anti-TIGIT and anti-CD96 antibodiesPharmaceuticalsAGENUS INC.
Jul 1, 202512,344,670Anti-ILT4 antibodies and antigen-binding fragmentsBiotechnologyAGENUS INC.
Mar 11, 202512,246,066Anti-CTLA-4 antibodies and methods of use thereofPharmaceuticalsAGENUS INC.
Jan 7, 202512,187,795Anti-LAG-3 antibodies and methods of use thereofPharmaceuticalsAGENUS INC.
Jun 18, 202412,011,481Anti-TIM-3 antibodies and methods of use thereofPharmaceuticalsAGENUS INC.
May 28, 202411,993,653Antibodies and methods of use thereofPharmaceuticalsAGENUS INC.
May 28, 202411,993,651Anti-lag-3 antibodies and methods of use thereofPharmaceuticalsAGENUS INC.
Feb 13, 202411,897,962Anti-GITR antibodies and methods of use thereofPharmaceuticalsAGENUS INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0360209ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOFPharmaceuticalsAgenus Inc.
Sep 11, 20252025/0282875METHODS OF TREATING COLORECTAL CANCER USING AN ANTI-CTLA4 ANTIBODYPharmaceuticalsAGENUS INC.
Jun 26, 20252025/0206818ANTI-LAG-3 ANTIBODIES AND METHODS OF USE THEREOFPharmaceuticalsAgenus Inc.
Apr 3, 20252025/0109201ANTI-ILT2 ANTIBODIES AND USES THEREOFBiotechnologyAgenus Inc.
Oct 31, 20242024/0360249HETERODIMERIC PROTEINSBiotechnologyAgenus Inc.
Jul 11, 20242024/0228614ANTI-ILT4 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTSBiotechnologyAGENUS INC. · patent 12,344,670 granted from it
Jun 27, 20242024/0209082ANTI-CD96 ANTIBODIES AND METHODS OF USE THEREOFPharmaceuticalsAgenus Inc.
Jun 6, 20242024/0181048ANTI-TIM-3 ANTIBODIES AND METHODS OF USE THEREOFPharmaceuticalsAgenus Inc.
May 2, 20242024/0141047ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOFBiotechnologyAgenus Inc.
May 2, 20242024/0141039ANTI-TIGIT AND ANTI-CD96 ANTIBODIESPharmaceuticalsAgenus Inc. · patent 12,479,913 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 6 · Biotechnology 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AGEN · research, not advice